Oncology Products

• BLENREP for injection is a sterile, preservative-free, white to yellow lyophilized powder for reconstitution and further dilution prior to intravenous use.
• BLENREP is supplied in a carton containing one 70 mg single-dose vial with a rubber stopper (not made with natural rubber latex) and aluminum overseal with removable cap (NDC 0173- 0913-01).
• BLENREP is a hazardous drug. Follow applicable special handling and disposal procedures.

Storage of unreconstituted vials

• Store vials refrigerated at 36ºF to 46ºF (2ºC to 8ºC).

Storage of reconstituted solution

• If the reconstituted solution is not used immediately, store in the original container refrigerated at 36ºF to 46ºF ( 2ºC to 8ºC ) or at room temperature (68°F to 77°F [20°C to 25°C]) for up to 4 hours. Discard if not diluted within 4 hours. Do not freeze.

Storage of diluted infusion solution

• If the diluted infusion solution is not used immediately, store refrigerated at 36ºF to 46ºF (2ºC to 8ºC) for up to 24 hours. Do not freeze. Once removed from refrigeration, administer the diluted infusion solution of BLENREP within 6 hours (including infusion time).

• JEMPERLI injection is a clear to slightly opalescent, colorless to yellow solution supplied in a carton containing one 500 mg/10 mL (50 mg/mL), single-dose vial (NDC 0173-0898-03).
• Store vial refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze or shake.

Storage of Infusion Solution

• Store in the original carton until time of preparation in order to protect from light. The prepared dose may be stored either:
  • At room temperature for no more than 6 hours from the time of preparation until the end of infusion.
  • Under refrigeration at 2°C to 8°C (36ºF to 46ºF) for no more than 24 hours from time of preparation until end of infusion.
• If refrigerated, allow the diluted solution to come to room temperature prior to administration.
• Discard after 6 hours at room temperature or after 24 hours under refrigeration.
• Do not freeze.

OJJAARA (momelotinib) tablets are available as follows:

• NDC Number: NDC 81864-103-30​ | Strength: 100 mg | Round-shaped brown film-coated tablet with “M” on one side and “100” on the other side.​ | Tablets per Bottle: 30 tablets
• NDC Number: NDC 81864-102-30​ | Strength: 150 mg​ | Triangular-shaped brown film-coated tablet with “M” on one side and “150” on the other side.​ | Tablets per Bottle: 30 tablets
• NDC Number​: NDC 81864-101-30​ | Strength: 200 mg. | ​Capsule-shaped brown film-coated tablet with “M” on one side and “200” on the other side.​ | 30 tablets per bottle​.

Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

Dispense to patient in original bottle only. Store in original bottle to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.

• ZEJULA is available as oval-shaped, film-coated tablets containing 100 mg, 200 mg, or 300 mg of niraparib free base.
• ZEJULA 100-mg tablets are gray, debossed with “100” on one side and “Zejula” on the other side. Bottle of 30 tablets (NDC 0173-0909-13).
• ZEJULA 200-mg tablets are blue, debossed with “200” on one side and “Zejula” on the other side. Bottle of 30 tablets (NDC 0173-0912-13).
• ZEJULA 300-mg tablets are green, debossed with “300” on one side and “Zejula” on the other side. Bottle of 30 tablets (NDC 0173-0915-13).
• Store and dispense in the original bottle. Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].